While CAR-T therapies have revolutionized treatment for blood cancers, their application in solid tumors remains limited by safety, scalability, and manufacturing hurdles. In an exclusive interview with GeneOnline, Kuo-Hsiang Chuang, CEO of CytoArm｜BsAb Armed-T Therapy Platform Revolutionizing T Cell Cancer Treatment, shared how the company is pioneering a non-viral T cell engineering platform to overcome these roadblocks.
CytoArm’s approach avoids genome editing entirely, instead “dressing” T cells with surface-bound bispecific molecules; a safer, faster, and more flexible strategy. Their lead candidate, CTA-02, is designed to deliver over 100 times the T cell dose of conventional CAR-T therapies, aiming to tackle hard-to-treat solid tumors like colorectal cancer.
As Chuang puts it, “We’re not just making another CAR-T, we’re building a new platform for safer, scalable, and adaptive immunotherapy.”
Check out the full interview article here:
English – https://bit.ly/45mGzs1
Chinese – https://bit.ly/3HmZJG4
